Receptos Announces Appointment of Erle T. Mast as Director

Receptos Announces Appointment of Erle T. Mast as Director

SAN DIEGO, July 22, 2013 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a
biopharmaceutical company developing therapeutic candidates for the treatment
of immune and metabolic diseases, today announced the appointment of Erle T.
Mast as a director of the Company. Mr. Mast will serve as a Class I director
with a term of office expiring at the first annual meeting of stockholders
following the date of his appointment.Mr. Mast will also serve as a member of
the Company's Audit Committee.Mr. Mast is a co-founder of Clovis Oncology,
Inc. and has served as its Executive Vice President and Chief Financial
Officer since 2009. Previously, Mr. Mast served in the same role at Pharmion
Corporation, beginning in 2002. From 1997 through 2002, Mr. Mast worked for
Dura Pharmaceuticals, Inc. and its successor, Elan Corporation. From 2000 to
2002, he served as Chief Financial Officer for the Global Biopharmaceuticals
business unit for Elan. From 1997 to 2000, Mr. Mast served as Vice President
of Finance for Dura Pharmaceuticals. Prior to that, Mr. Mast was a partner
with Deloitte & Touche, LLP. Mr. Mast also serves on the board of directors
Zogenix, Inc. Mr. Mast received a B.Sc. in business administration from
California State University Bakersfield.

Faheem Hasnain, President and Chief Executive Officer of the Company, said,
"We are pleased to welcome Erle to the Receptos Board of Directors. He has
extensive experience in the biotechnology industry and financial expertise
with life science companies.We expect that Erle will provide valuable
strategic contributions as a Board member and we look forward to working with
him."

AboutReceptos

Receptos is a biopharmaceutical company developing therapeutic candidates for
the treatment of immune and metabolic diseases. The company's lead program,
RPC1063, is a sphingosine 1-phosphate 1 receptor (S1P1R) small molecule
modulator candidate for immune indications, including relapsing multiple
sclerosis (RMS) and inflammatory bowel disease (IBD). The company is also
developing RPC4046, an anti-interleukin-13 (IL-13) antibody for an
allergic/immune-mediated orphan disease, eosinophilic esophagitis (EoE).
Receptos has established expertise in high resolution protein crystal
structure determination, biology and drug discovery for G-protein-coupled
receptors (GPCRs).

CONTACT: Media and Investor Contact:
         Graham K. Cooper
         Chief Financial Officer, Receptos
         (858) 652-5708
         gcooper@receptos.com

Receptos Logo
 
Press spacebar to pause and continue. Press esc to stop.